Neglected Tropical Disease Treatment Market By Drug Class-
Neglected Tropical Disease Treatment Market By Disease Type-
Neglected Tropical Disease Treatment Market By Distribution Channel-
Neglected Tropical Disease Treatment Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neglected Tropical Disease Treatment Market Snapshot
Chapter 4. Global Neglected Tropical Disease Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Neglected Tropical Disease Treatment Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Neglected Tropical Disease Treatment Industry Trends
Chapter 5. Neglected Tropical Disease Treatment Market Segmentation 1: By Drug Class, Estimates & Trend Analysis
5.1. Market Share by Drug Class, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Class:
5.2.1. Anti-Parasite
5.2.2. Antifungal
5.2.3. Antibiotics
5.2.4. Others
Chapter 6. Neglected Tropical Disease Treatment Market Segmentation 2: By Disease Type, Estimates & Trend Analysis
6.1. Market Share by Disease Type, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Disease Types:
6.2.1. Leishmaniasis
6.2.2. Schistosomiasis
6.2.3. Lymphatic Filariasis
6.2.4. Chagas Disease
6.2.5. African Trypanosomiasis
6.2.6. Others
Chapter 7. Neglected Tropical Disease Treatment Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channels:
7.2.1. Direct Sales
7.2.2. Indirect Sales
Chapter 8. Neglected Tropical Disease Treatment Market Segmentation 6: Regional Estimates & Trend Analysis
8.1. Global Neglected Tropical Disease Treatment Market, Regional Snapshot 2023 & 2031
8.2. North America
8.2.1. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.2.3. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.2.4. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.3. Europe
8.3.1. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.3.3. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.3.4. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.4. Asia Pacific
8.4.1. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.4.3. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.4.4. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
8.5. Latin America
8.5.1. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.5.3. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.5.4. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.6. Middle East & Africa
8.6.1. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.6.3. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.6.4. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Thermo Fisher Scientific, Inc.
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service Offerings
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. F. Hoffmann-La Roche Ltd.
9.2.3. Omega Diagnostics Group PLC
9.2.4. Abbott
9.2.5. Oscar Medicare Pvt. Ltd.
9.2.6. Merck Ltd.
9.2.7. Genome Diagnostics Pvt. Ltd.
9.2.8. ZeptoMetrix
9.2.9. Bayer AG,
9.2.10. GlaxoSmithKline plc
9.2.11. Novartis AG
9.2.12. Pfizer, Inc.
9.2.13. Eisai Co. Ltd.
9.2.14. Sanofi
9.2.15. Astellas Pharma
9.2.16. Takeda Pharmaceutical Company Limited
9.2.17. Gilead Sciences
9.2.18. Other Market Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.